Entrepreneur UK's London 100: elasticStage
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media.
Industry: Music Technology
elasticStage is a deserving company on the Entrepreneur UK London100 list being the first platform in the world to make on-demand, commercial-quality records — with no warehousing, no upfront costs, and no minimum orders. Just real vinyl, made one at a time, exactly when a fan hits "buy." Thanks to a once-in-a-generation breakthrough in production tech, elasticStage gives independent artists the power to sell physical music directly to fans with zero risk and full control.
Founded in London by Steve Rhodes and Werner Freistaetter, elasticStage is backed by icons like Calvin Harris and Paul Epworth. A global wave of independent, self-releasing artists is reshaping the music landscape. Now more than 50m strong and growing by 30% each year, this group is the fastest-rising force in the industry — and the most underserved. These creators want to connect directly with listeners, build lasting fan relationships, and earn a fair income from their work. But the tools available to them haven't kept up. Streaming platforms dominate attention, but offer little in return: royalties are diluted, and the artist-fan connection is weak. Physical music, by contrast, offers higher value and deeper engagement - but traditional vinyl production was never built for small independent creators. It comes with long lead times, high costs, and outdated systems that shut them out - and it hasn't changed in 50 years.
Developed over nine years and backed by tens of millions in investment, elasticStage's proprietary production technology is the first major innovation in vinyl production in over 50 years.
This breakthrough means artists don't face upfront capital requirements, inventory costs, or minimum orders — transforming a once high-barrier format into an accessible, creator-first channel.
Orders are fulfilled in just days rather than months, allowing artists to offer their fans collectible, high-quality physical music without the risks and logistical challenges of traditional production.
Since launching its online platform in October 2024, elasticStage has already onboarded almost 20,000 creators in almost 100 countries, and released projects with artists including Boy George and Hannah Laing. It has also formed partnerships with leading music companies and platforms such as The Orchard, BMG, Marathon Music Group, Three Six Zero, SoundCloud, and CTRLFRK.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
Yahoo
39 minutes ago
- Yahoo
Food delivery service Calo scores $39 million in Series B extension as it sets eyes on the UK
Middle Eastern food delivery startup Calo said Tuesday it has raised $39 million in a Series B extension that was led by AlJazira Capital. The fundraise, which was more than 1.5x of its original $25 million raise in December, also saw participation from existing backers such as Nuwa Capital, STV, Khwarizmi Ventures, and Al Faisaliah Group. The company is using this funding to expand into territories like the UK and also explore different partnerships in physical space. Calo primarily offers ready-to-eat meals that customers can heat up later. The company delivers different plans to cater to various health goals. The company's founder, Ahmed Al Rawi, told TechCrunch the startup's revenue grew by 'close to 100%.' Calo delivered more than 10 million meals last year in Saudi Arabia, the UAE, Kuwait, Qatar, and Bahrain. While Al Rawi didn't provide a number for this year, he said the deliveries were growing in step with revenue. Those numbers, along with its brand, technology, and operational excellence, convinced AlJazira Capital to invest in the Saudi company. 'Calo represents a compelling opportunity at the intersection of healthtech, foodtech, and consumer subscription models,' Rawan AlRasheed, director of venture capital at AlJazira Capital told TechCrunch in a statement. The startup is also making moves to expand in the UK, where last year it acquired two meal delivery services, Fresh Fitness Food and Detox Kitchen. While Fresh Fitness Food didn't raise any money, Detox Kitchen had raised just over $3.4 million via a mix of venture-backed and equity crowdfunding rounds, according to Crunchbase data. 'We spoke to over 50 meal subscription businesses worldwide, ranging from the U.S. to Asia, in 2023-24 to learn about what is an exciting market for us to expand to. We realized the UK was the right market for us to expand. We thought that both companies that we acquired had a great culture fit to work with Calo,' Al Rawi told TechCrunch over a call. He added that Calo acquired these businesses because they had their operational layer figured out, and the startup just wanted to upscale the tech and branding layer. Al Rawi said Calo spent most of this year integrating its technology and process with both UK platforms without laying off any of the existing personnel. The startup finished the integration work in July and has been slowly making a marketing push in the UK. Calo can currently deliver meals in London daily and in other parts of the UK two to three times a week. The founder said that Calo is targeting to get to 10x its revenue in the UK in the next three years. Those UK ambitions will be met with competition. Apart from traditional food delivery giants like Just Eat and Deliveroo, Calo will also compete with meal-box services such as Gusto and Wicked Kitchen. While Calo is focused on growing in the UK, the company is also looking to acquire different meal-kit services across the world. The company is also expanding physical locations, including retail stores and kiosks in other regions. The company has also partnered with a gym chain called Armah Sports Company in Saudi Arabia to offer a bundle of Calo and gym subscription. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
The Nutriment Company acquires cat food supplier Purrform
Acquisitive pet-food group The Nutriment Company has snapped up another UK business, buying cat-food supplier Purrform. Financial terms were not disclosed. In a statement, The Nutriment Company said the deal 'adds a new dimension of species-specific expertise to its brand portfolio'. Founded in 2011, Purrform offers recipes said to closely mirror a cat's natural prey-based diet. According to The Nutriment Company, it uses 100% human-grade meat, offal and bone, free from preservatives or additives. The Stockholm-headquartered group believes Purrform's acquisition 'comes at a strategic time' as cat ownership is rising across Europe. Citing FEDIAF, a trade body representing the European pet food industry, The Nutriment Company said approximately 108 million cats live in European households, highlighting the 'significant market potential for natural nutrition tailored specifically for cats'. As part of The Nutriment Company, Purrform's products are expected to become 'more available in retail' with support from the wider group's 'extensive distribution network', reaching stores across the UK and continental Europe. Anders Kristiansen, CEO of The Nutriment Company, said Purrform's 'heart-felt dedication to crafting species-appropriate, high-quality meals for cats aligns perfectly with our mission'. He added: 'We are excited to help scale Purrform's impact and bring their unique offering to more cat owners across Europe.' Veronique Ornech, founder and managing director of Purrform, added under the new owners 'the brand will not only remain true to its roots but reach exciting new heights'. She added: 'Together, we are not just continuing the journey, we are accelerating it.' Backed by Nordic PE investor Axcel, The Nutriment Company offers 'natural premium' pet food under brands such as Dibo, Barfgold, and AniForte. Purrform is the latest in a series of acquisitions in 2025. The company purchased Graf Barf, a German private-label pet-food business, from CDS Hackner in June. Graf Barf's acquisition came two months after The Nutriment Company acquired BAF Petfood from the German company Fressnapf. In April, The Nutriment Company took over Bulmer Pet Foods, a UK-based firm. Additionally, in February, the pet-food supplier expanded into the Spanish market by acquiring Puromenu, a producer of raw pet food. "The Nutriment Company acquires cat food supplier Purrform " was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
